Benitec Biopharma(BNTC) - 2025 Q3 - Quarterly Results

Financial Performance - Total expenses for Q3 2025 were $10.2 million, up from$4.1 million in Q3 2024, representing a 148.8% increase[4] - The net loss attributable to shareholders for Q3 2025 was $9.4 million, or$0.24 per share, compared to a net loss of $4.3 million, or$0.23 per share in Q3 2024[5] - The company reported a total comprehensive loss of $9.4 million for Q3 2025, compared to a comprehensive loss of$4.2 million in Q3 2024[9] - Total operating expenses for the nine months ended March 31, 2025, were $24.6 million, compared to$16.9 million for the same period in 2024, indicating a 45.5% increase[9] Research and Development - Research and development expenses for the quarter were $6.0 million, compared to$2.6 million in the same quarter last year, marking a 130.8% increase[4] - The company is focused on the continued development of BB-301 for the treatment of dysphagia in OPMD patients[3] - The company plans to enroll additional subjects at a higher dose of BB-301 later this year, following the successful treatment of the sixth subject in Cohort 1[3] Assets and Cash Position - As of March 31, 2025, the company had $103.6 million in cash and cash equivalents, an increase from$50.9 million as of June 30, 2024[7] - The total assets as of March 31, 2025, were $105.2 million, compared to$52.2 million as of June 30, 2024, reflecting a 101.5% increase[7] Earnings Per Share - The basic earnings per share calculation has been revised to include pre-funded warrants in the weighted number of shares outstanding for the current and comparative periods[5]